Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Summary

Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as patients with metastatic colorectal cancer who have exposure to 2 or more lines of chemotherapy, to evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with poly-ICLC adjuvant in combination with nivolumab and ipilimumab.

Timeline

Start

2020-05-28

Primary completion

2027-06-01

Completion

2027-06-01

Publications

• Huff AL, Haldar SD, Girgis AA, Wang HH, Danilova L, Heumann T, Berg M, Wang Y, Andaloori L, Hernandez A, Longway G, Barrett B, Zhu Z, Davis-Marcisak E, Thoburn C, Leatherman J, Mitchell S, Lee JW, Shu DH, Konig MF, Mog BJ, Montagne J, Coyne EM, Bever K, Baretti M, Yarchoan M, Anders RA, Kagohara LT, Laheru D, Thomas AM, Durham J, Nauroth JM, Lu J, Wang H, Fertig EJ, Ho WJ, Azad NS, Jaffee EM, Zaidi N. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Nat Commun. 2026 Feb 10;17(1):1538. doi: 10.1038/s41467-026-68324-4.

Drugs

Indications